Publications for Michael B. Clearfield michael.clearfield@tu.edu

College of Osteopathic Medicine (TUC)
  • Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., . . . Clearfield, M. B. (2015). The effect of statin therapy on heart failure events: A collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36, 1536-1546. doi:10.1093/eurheartj/ehv072

  • Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., . . . Clearfield, M. B. (2014). Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials. Journal of the American College of Cardiology, 64(5), 485-494. doi:10.1016/j.jacc.2014.02.615

  • Clearfield, M. B., Pearce, M., Nibbe, Y., Crotty, D., & Wagner, A. (2014). The "new deadly quartet" for cardiovascular disease in the 21st century: Obesity, metabolic syndrome, inflammation and climate change: How does statin therapy fit into this equation? Current Atherosclerosis Reports, 16(1) [Article 380]. doi:10.1007/s11883-013-0380-2

  • Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., . . . Clearfield, M. (2013). Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation, 128(14), 1504-1512.  doi:10.1161/CIRCULATIONAHA.113.002670

  • Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., Macfadyen, J., Zaharris, E., . . . Clearfield, M. (2013). Rationale and design of the cardiovascular inflammation reduction trial: A test of the inflammatory hypothesis of atherothrombosis. American Heart Journal, 166(2), 199–207.  doi:10.1016/j.ahj.2013.03.018

  • Rehfield, P., Kopes-Kerr, C., & Clearfield, M. (2013). The evolution or revolution of statin therapy in primary prevention: Where do we go from here? Current Atherosclerosis Reports, 15(2), 298.  doi:10.1007/s11883-012-0298-0

  • Truong, T. T., & Clearfield, M. (2013). Acute coronary syndromes in patients without elevated low-density lipoprotein (LDL) cholesterol not predicted by serum phytosterols. Journal of the American Osteopathic Association, 113(8), e14.

  • Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., . . . Clearfield, M. B. (2012). Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA, 307(12), 1302-1309. doi:10.1001/jama.2012.366

  • Clearfield, M. B. [Contributor for Cholesterol Treatment Trialists' (CTT) Collaboration]. (2012). Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin. PLos One, 71(1) [Article e29849]. doi:10.1371/journal.pone.0029849

  • Clearfield, M. B. [Contributor for Cholesterol Treatment Trialists' (CTT) Collaboration]. (2012). The effects of lowering LDL-C with statin therapy in people at low risk of vascular disease: A meta-analysis of individual data from 27 randomized trials. The Lancet, 380(9841), 581-590. PMCID: PMC3437972

  • Clearfield, M. B. (2011, April). Cardiovascular benefits of aggressive cholesterol-lowering therapy. Journal of the American Osteopathic Association, 111(4 Suppl. 3), i-eS2.

  • Clearfield, M. B. (2011). Combination lipid therapy in type 2 diabetes. Current Atherosclerosis Reports, 13(1), 1-3. doi:10.1007/s11883-010-0139-y

  • Clearfield, M. B. (2011). Statins in combination: From ARBITER-6 HALTS to ACCORD. What works? Current Atherosclerosis Reports, 13(1), 4-8. doi:10.1007/s11883-010-0142-3

  • Cholesterol Treatment Trialists' Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. Clearfield, M. B." href="http://dx.doi.org/10.1016/S0140-6736(10)61350-5" target="_blank">doi:10.1016/S0140-6736(10)61350-5

  • Clearfield, M. B. (2010). Altering the pathophysiology of atherosclerosis: The multidimensional role of statins. Journal of the American Osteopathic Association, 110(4 Suppl. 4), 2-6. This material can be found here.

  • Clearfield, M. B. (2010). Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Current Atherosclerosis Reports, 12(1), 8-10. doi:10.1007/s11883-009-0083-x

  • Clearfield, M. B. (2010). New evidence extending the benefit of treating LDL-C beyond the current guidelines. Current Atherosclerosis Reports, 12(1), 1-4. doi:10.1007/s11883-009-0081-z

  • Clearfield, M. B. (2010). Rosuvastatin and clinical outcomes in individuals who are not deemed appropriate for baseline statin therapy. Current Atherosclerosis Reports, 12(1), 5-7. doi:10.1007/s11883-009-0082-y

  • Hiserote, P., & Clearfield, M. B. (2010). Treating risk components of the metabolic syndrome. Journal of the American Osteopathic Association, 110 (3, Suppl. 3), 6-13. This material can be found here.

  • Satter, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J. M., . . . Clearfield, M. B. (2010). Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. The Lancet, 375(9716), 735-742. doi:10.1016/S0140-6736(09)61965-6

  • Bray, G. A., Clearfield, M. B., Fintel, D. J., & Nelinson, D. S. (2009). Overweight and obesity: The pathogenesis of cardiometabolic risk. Clinical Cornerstone, 9(4), 30-42. doi: 10.1016/S1098-3597(09)80003-3 This material can be found here.

  • Cui, Y., Watson, D. J., Girman, C. J., Shapiro, D. R., Gotto, A. M., Hiserote, P., & Clearfield, M. B. (2009). Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology, 104(6), 829-834. This material can be found here.

  • Licciardone, J. C., Clearfield, M. B., & Guillory, V. J. (2009). Clinical practice characteristics of osteopathic and allopathic primary care physicians at academic health centers: Results from the National Ambulatory Medical Care Survey. Academic Medicine, 84(6), 744-750. doi: 10.1097/ACM.0b013e3181a424fc This material can be found here.

  • Shah, B. M., Kemp, R., & Clearfield, M. B. (2009) Using statins to treat healthy patients – are we there yet? Expert Review of Pharmacoeconomics and Outcomes Research, 9(2), 103-105. doi: 10.1586/erp.09.5 This material can be found here.